ENOV - Enovis Corporation

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $45.80 DETAILS

Stock News

ront Street Bought 384K More Shares of Enovis in Q1. Is ENOV a Buy Now?

Enovis develops orthopedic and rehabilitation devices for healthcare providers, serving a broad spectrum of musculoskeletal patient needs.

May 22, 2026 04:08 PM • fool.com

Does Enovis (ENOV) Have the Potential to Rally 65.45% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 65.5% in Enovis (ENOV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

May 13, 2026 06:55 AM • zacks.com

Enovis Q1 Earnings Call Highlights

Enovis NYSE: ENOV reported a solid start to 2026, with management pointing to share gains in its reconstructive surgery business, stable growth in prevention and recovery, and continued investment in new products including ARVIS and Nebula.

May 10, 2026 12:07 AM • marketbeat.com

Enovis Corporation (ENOV) Q1 2026 Earnings Call Transcript

May 07, 2026 11:11 AM • seekingalpha.com

Enovis (ENOV) Q1 Earnings and Revenues Beat Estimates

Enovis (ENOV) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.82 per share. This compares to earnings of $0.81 per share a year ago.

May 07, 2026 04:46 AM • zacks.com

Enovis Announces First Quarter 2026 Results

Dallas, TX, May 07, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 3, 2026. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.

May 07, 2026 02:01 AM • globenewswire.com

Enovis (ENOV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Enovis (ENOV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Apr 30, 2026 07:06 AM • zacks.com

Is Enovis Corp (ENOV) a Bargain After 4.7% Drop? GF Value Says Undervalued

On April 28, 2026, Enovis Corp (ENOV) shares fell 4.7% today, closing at $23.40. The stock has experienced a 52-week range of $21.00 to $37.85, indicating signi

Apr 28, 2026 02:32 PM • gurufocus.com

Omnicell (OMCL) Q1 Earnings and Revenues Surpass Estimates

Omnicell (OMCL) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.26 per share a year ago.

Apr 28, 2026 04:55 AM • zacks.com

Despite Fast-paced Momentum, Enovis (ENOV) Is Still a Bargain Stock

Enovis (ENOV) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Apr 22, 2026 05:56 AM • zacks.com

Analyst Backs Enovis On Cash Flow Turnaround

The firm argued that while the stock has lagged over the past two years, execution on cash flow could unlock multiple expansion opportunities.

Apr 17, 2026 09:45 AM • benzinga.com

Enovis Corporation (NYSE:ENOV) Receives Consensus Rating of “Buy” from Analysts

Enovis Corporation (NYSE: ENOV - Get Free Report) has earned a consensus rating of "Buy" from the nine analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average

Apr 15, 2026 12:27 AM • defenseworld.net

Head to Head Contrast: HeartBeam (NASDAQ:BEAT) versus Enovis (NYSE:ENOV)

HeartBeam (NASDAQ: BEAT - Get Free Report) and Enovis (NYSE: ENOV - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, institutional ownership, profitability and dividends. Volatility and Risk HeartBeam has a beta of -0.63,

Apr 14, 2026 10:26 PM • defenseworld.net

Enovis to Host First Quarter 2026 Results Conference Call on May 7th

Dallas, TX, April 10, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2026 financial results on Thursday, May 7th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Enovis' website at www.enovis.com .

Apr 10, 2026 04:00 AM • globenewswire.com

Wall Street Analysts See a 100.71% Upside in Enovis (ENOV): Can the Stock Really Move This High?

The consensus price target hints at a 100.7% upside potential for Enovis (ENOV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Mar 24, 2026 06:56 AM • zacks.com

Royce Small-Cap Fund FY 2025: What Worked

Five of the Fund's 10 equity sectors made a positive impact on calendar year performance, led by Industrials, Financials, and Information Technology. Alamos Gold's positive earnings outlook, a renewed stock buyback program, and rising gold prices all helped its stock to climb throughout 2025. Management reported a 48% increase in total revenue for 1Q25 compared to 1Q24, driven by OCS liver and heart transplants.

Mar 08, 2026 11:55 PM • seekingalpha.com

Wall Street Analysts Think Enovis (ENOV) Could Surge 76.62%: Read This Before Placing a Bet

The mean of analysts' price targets for Enovis (ENOV) points to a 76.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Mar 05, 2026 05:56 AM • zacks.com

American Century Companies Inc. Sells 258,262 Shares of Enovis Corporation $ENOV

American Century Companies Inc. reduced its holdings in shares of Enovis Corporation (NYSE: ENOV) by 5.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,731,065 shares of the company's stock after selling 258,262 shares during the quarter. American Century Companies

Mar 01, 2026 10:08 PM • defenseworld.net

Enovis Q4 Earnings Call Highlights

Enovis (NYSE: ENOV) reported fourth-quarter and full-year 2025 results that management said reflected "strong performance" across its global organization, while also acknowledging execution shortcomings late in the year and outlining a 2026 outlook that targets continued organic growth, margin expansion, and a step-up in free cash flow conversion. 2025 results: solid organic growth and improved cash

Feb 27, 2026 09:38 PM • defenseworld.net